Market Overview:
The Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The market growth factors include the increasing prevalence of cancer, technological advancements in kinase inhibitors, and rising investments by key players in this market. However, the high cost of treatment and lack of awareness about dual specificity tyrosine phosphorylation regulated kinases 1A are some factors that may hamper the growth of this market. Based on type, PST-900 is expected to be the fastest growing segment during the forecast period from 2018 to 2030. This is due to its ability to inhibit multiple kinases simultaneously and its potential for use as a therapeutic agent against various cancers.
Product Definition:
Dual specificity tyrosine phosphorylation regulated kinase 1A (DUSP1) is a protein that in humans is encoded by the DUSP1 gene. The protein encoded by this gene belongs to the dual specificity mitogen-activated protein kinase (MAPK) family. It is a negative regulator of MAPK signaling pathways and has been shown to be involved in both apoptosis and proliferation.
PST-900:
PST-900 is a dual specificity tyrosine phosphorylation regulated kinase 1A (PDK1A) inhibitor. It is an investigational drug developed by SK Life Sciences and was first reported in 2015.
NNI-351:
NNI-351 is a novel chemical entity developed by Cereda Therapeutics for the treatment of patients with multiple myeloma and lymphoblastic leukemia. NNI-351 has shown potent cytoprotective effects in vitro and in vivo, which may be attributed to its ability to regulate both tyrosine phosphorylation regulated kinase 1A (PRAK1A) activity as well as nuclear factor B ligand (NFB)-2/3 activation.
Application Insights:
The colon cancer segment dominated the overall market in terms of revenue generation in 2017. This can be attributed to the rising prevalence of colorectal cancer and increasing awareness about DSRK1A. PST-901 is a dual specificity tyrosine phosphorylation regulated kinase 1 inhibitor under investigation for the treatment of advanced stages of colon and rectal cancers. It has been granted Fast Track status by U.S FDA for its potential to reduce tumor burden in patients with metastatic breast carcinoma and locally advanced or metastatic non-small cell lung cancer (NSCLC).
DSRK1 plays an important role in controlling cell proliferation, migration, adhesion, invasiveness, angiogenesis as well as tumorigenesis through its downstream signaling pathways such as Akt/PKB activation pathway and nuclear factor Žº-B signaling pathway which are associated withcolon carcinogenesis.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key players, increased research and development activities, and high healthcare expenditure in this region. Moreover, increasing cases of cancer are also contributing toward regional growth. For instance, according to the American Cancer Society Inc., more than 1.7 million people were diagnosed with new cancers in 2016 in the U.S.
Growth Factors:
- Increasing demand for novel cancer therapies
- Growing prevalence of cancer
- Rising awareness about DS-TPRK1A as a potential therapeutic target for various cancers
- Technological advancements in the field of kinase inhibitors research and development
- increasing investment in kinase inhibitor research
Scope Of The Report
Report Attributes
Report Details
Report Title
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Research Report
By Type
PST-900, NNI-351, FX-9847, Others
By Application
Colon Cancer, Down Syndrome, Lung Cancer, Pancreatic Cancer, Others
By Companies
Carna Biosciences Inc, Felicitex Therapeutics, ManRos Therapeutics, NeuroNascent Inc, Pharmasum Therapeutics AS, Carna Biosciences Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Report Segments:
The global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A market is segmented on the basis of:
Types
PST-900, NNI-351, FX-9847, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colon Cancer, Down Syndrome, Lung Cancer, Pancreatic Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Carna Biosciences Inc
- Felicitex Therapeutics
- ManRos Therapeutics
- NeuroNascent Inc
- Pharmasum Therapeutics AS
- Carna Biosciences Inc
Highlights of The Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PST-900
- NNI-351
- FX-9847
- Others
- By Application:
- Colon Cancer
- Down Syndrome
- Lung Cancer
- Pancreatic Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dual specificity tyrosine phosphorylation regulated kinase 1A (DSTK1A) is a protein that in humans is encoded by the DSTK1A gene. This gene encodes a member of the dual specificity tyrosine phosphorylation regulated kinases family. The protein has two distinct catalytic domains, one for serine/threonine-specific and another for tyrosine-specific phosphorylation. This enzyme plays an important role in controlling cellular signaling pathways by regulating the activity of several proteins involved in cell growth, survival, and motility.
Some of the key players operating in the dual specificity tyrosine phosphorylation regulated kinase 1a market are Carna Biosciences Inc, Felicitex Therapeutics, ManRos Therapeutics, NeuroNascent Inc, Pharmasum Therapeutics AS, Carna Biosciences Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Size & Forecast, 2020-2028
4.5.1 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Size and Y-o-Y Growth
4.5.2 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 PST-900
5.2.2 NNI-351
5.2.3 FX-9847
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colon Cancer
6.2.2 Down Syndrome
6.2.3 Lung Cancer
6.2.4 Pancreatic Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 PST-900
9.6.2 NNI-351
9.6.3 FX-9847
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colon Cancer
9.10.2 Down Syndrome
9.10.3 Lung Cancer
9.10.4 Pancreatic Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 PST-900
10.6.2 NNI-351
10.6.3 FX-9847
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colon Cancer
10.10.2 Down Syndrome
10.10.3 Lung Cancer
10.10.4 Pancreatic Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 PST-900
11.6.2 NNI-351
11.6.3 FX-9847
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colon Cancer
11.10.2 Down Syndrome
11.10.3 Lung Cancer
11.10.4 Pancreatic Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 PST-900
12.6.2 NNI-351
12.6.3 FX-9847
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colon Cancer
12.10.2 Down Syndrome
12.10.3 Lung Cancer
12.10.4 Pancreatic Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 PST-900
13.6.2 NNI-351
13.6.3 FX-9847
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colon Cancer
13.10.2 Down Syndrome
13.10.3 Lung Cancer
13.10.4 Pancreatic Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market: Competitive Dashboard
14.2 Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Carna Biosciences Inc
14.3.2 Felicitex Therapeutics
14.3.3 ManRos Therapeutics
14.3.4 NeuroNascent Inc
14.3.5 Pharmasum Therapeutics AS
14.3.6 Carna Biosciences Inc
